No abstract

Objective. The levels of vitamin D, trace elements, and glucose and lipid metabolism in psoriasis were evaluated, and their value in disease diagnosis and severity evaluation was explored. Methods. In this study, the serum trace elements, blood glucose, and blood lipid indexes of 360 patients with psoriasis and 500 healthy subjects were compared and analyzed. Results. The results of 25-(OH) D3, Cu/Zn, and HDL-C in patients with psoriasis were significantly different from those in the control group. With the aggravation of the disease, Psoriasis Area and Severity Index (PASI) was positively correlated with 25-(OH) D3 and HDL-C and negatively correlated with Cu/Zn. The AUC of the three indexes for the diagnosis of psoriasis was 0.899, 0.675, and 0.848, respectively. Conclusion. There are metabolic abnormalities of 25-(OH) D3, Cu/Zn, and HDL-C in patients with psoriasis, and paying attention to these indicators is conducive to the diagnosis of disease.

presented an editorial for publication titled, "Cardiac Arrest Following Regional Anesthesia with Etidocaine or Bupivacaine." Starting in 1963, bupivacaine became a promising local anesthetic used around the world. At a time when bupivacaine during obstetric anesthesia was a standard practice, George Albright's manuscript reported 5 cases showed that bupivacaine was associated with an increased mortality rate compared with other local anesthetics during epidurals or brachial plexus blocks. Raising the question of bupivacaine cardiotoxicity and calling for further investigation of bupivacaine use sparked controversy. C. Philip Larson, MDCM, MS, Professor and Chair of the Department of Anesthesia at Stanford and Editor-in-Chief of Anesthesiology at the time of Dr. Albright's editorial submission, decided to publish the piece despite it receiving harsh criticism from expert reviewers. Dr Albright's controversial editorial ultimately led to several important anesthesiology advancements, including laboratory studies proving bupivacaine cardiotoxicity, the discontinuation of bupivacaine 0.75% epidurally in clinic, safeguards before incremental anesthetic injection, development of less toxic local anesthetics, and further research into intravenous lipid emulsion to counteract adverse effects of bupivacaine cardiotoxicity. Stemming from Dr. Albright's research, from 1983 to 1999, the US Food and Drug Administration (FDA) issued a black box warning against 0.75% bupivacaine use during obstetric anesthesia.Dr. Albright had a productive career and left a legacy.